Table 3. Most frequently reported nonhaematological treatment-related adverse events (N=60).
|
Toxicity according to NCI CTC grade (% of patients)
|
||||||
|---|---|---|---|---|---|---|
|
Cycle 1 (XELOX pre-radiotherapy)
|
Cycles 2 and 3 (CAPOX radiotherapy)
|
|||||
| Adverse event | 1/2 | 3 | 4 | 1/2 | 3 | 4 |
| Diarrhoea | 12 | 10 | — | 38 | 10 | — |
| Nausea/vomiting | 29 | 3 | — | 15 | — | — |
| Mucositis | — | 2 | — | 27 | 3 | — |
| Bleeding | 2 | — | — | 3 | 2 | — |
| Constipation | 7 | — | — | 3 | — | — |
| Pain | 7 | 3 | — | 40 | 2 | — |
| Fatigue | 15 | 2 | — | 28 | — | — |
| Infection | — | — | 2 | 12 | — | — |
| Hypokalaemia | — | 2 | — | — | 2 | — |
| Anorexia | 6 | 2 | — | 8 | 2 | — |
| Neuropathy | 27 | — | — | 30 | — | — |
| Dysuria | 5 | — | — | 32 | — | — |
| Syncope | — | 2 | — | — | — | — |
| Dyspnoea | 3 | — | — | 3 | 2 | — |
| Hand–foot syndrome | 2 | — | — | 6 | 2 | — |
| Dermatitis | 3 | — | — | 3 | — | — |
| Rash | 3 | — | — | 3 | — | — |
| Thrombosis | — | — | — | — | 3 | — |
NCI CTC=National Cancer Institute Common Terminology Criteria.